Lipitor Antitrust Settlement



If you purchased, paid, or provided reimbursement for some or all of the purchase price of branded Lipitor® or generic atorvastatin calcium, you could get a payment from the $35 Million thus far recovered in class-action settlements.



Settlement Amount: $35,000,000


SIGN UP TO PARTICIPATE

Deadline: November 29, 2024



Class Members:



Entities that, for consumption by its members, employees, insureds, participants, or beneficiaries, purchased, paid, and/or provided reimbursement for some or all of the purchase price of branded Lipitor or generic atorvastatin calcium, in Arizona, California, the District of Columbia, Florida, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, South Dakota, Tennessee, West Virginia, or Wisconsin. (the “Class States”), other than for resale, at any time during the period from June 28, 2011 through and until December 31, 2012.
Excluded from the TPP Class are (a) Pfizer, Ranbaxy, and their respective subsidiaries and affiliates (b) Federal and state governmental entities (c) Medicare Part D Plans and (d) Medicaid Plans


Damage Period:



  • June 28, 2011–December 31, 2012


Claim Based On:



The amount paid and/or reimbursed for Lipitor and AB-rated generic versions of Lipitor purchased in the Class States from June 28, 2011 through and until December 31, 2012



Defendants:



• Pfizer, Pfizer Ireland Pharmaceuticals, Warner-Lambert Company (collectively, “Pfizer”)

• Ranbaxy, Ranbaxy Laboratories Limited, and/or Ranbaxy Pharmaceuticals (collectively, “Ranbaxy”) ​



Background:



Plaintiffs allege that Pfizer fraudulently obtained a patent from the United States Patent and Trademark Office (PTO) and used that patent to wrongfully sue manufacturers that were applying to make, use, or sell generic versions of Lipitor, to delay generic versions of Lipitor from coming to market. Plaintiffs claim Pfizer then settled those lawsuits by agreeing to pay the generic manufacturers if they agreed to delay selling their generic versions of Lipitor. Plaintiffs further allege that Pfizer and Ranbaxy entered into an unlawful market-allocation agreement, in which Pfizer paid generic manufacturer Ranbaxy to delay entering the U.S. market with its generic version of Lipitor. Ranbaxy agreed to certain other measures that had the intended effect of delaying market entry of other would -be generic Lipitor manufacturers.


Defendants deny these allegations, including that Plaintiffs or Class Members are entitled to damages or other relief.



This is not an official Court Notice. Information contained in this Summary is subject to change.



CLASS ACTION REFUND, LLC





7901 4th Street N, Suite 13892
Saint Petersburg, FL 33702
PH: (727) 266-0433



Class Action Refund Center and the green arrow are trademarks of Class Action Refund, LLC a Florida Limited Liability Company.

Not affiliated with Class Action Recovery, LLC dba Class Action Refund in Harrison, NY